Diagnostics of aberrant cancer glycosylation signatures

Informazioni relative al progetto

SweetCancerTest

ID dell’accordo di sovvenzione: 101069379

DOI

10.3030/101069379

Progetto chiuso

Data della firma CE 16 Giugno 2022

Data di avvio 1 Luglio 2022

Data di completamento 31 Dicembre 2023

Finanziato da

• European Research Council (ERC)

Costo totale

Nessun dato

Contributo UE

€ 150 000,00

Coordinato da

TEL AVIV UNIVERSITY
Israel

Periodic Reporting for period 1 - SweetCancerTest (Diagnostics of aberrant cancer glycosylation signatures)

Periodo di rendicontazione: 2022-07-01 al 2023-12-31

Sintesi del contesto e degli obiettivi generali del progetto

Cancer is a leading cause of death worldwide and novel diagnostic and therapeutic approaches are much needed. All living cells are covered with a dense layer of ‘sugar-coat’ that is altered in cancer. One of the hallmarks of cancer is the expression of aberrant cell surface glycosylation patterns compared to normal cells. Current antibody-based assays against cancer glycans are commonly utilized to monitor clinical response to therapy, however none is useful for early detection or diagnosis due to low sensitivity and specificity. We aimed to develope a unique system for novel cancer diagnostics based on cancer glycosylation. Such validated tools could be used to identify cancer at an early stage and also for optimizing therapy to patients of unique sugar-code signatures.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

Sialic acids cover cell surface glycans and frequently have altered expression on many types of carcinoma cells and correlate with cancer progression and/or metastasis. We investigated sialic acid-containing carbohydrate-neoantigens as targets for cancer diagnostics based on unique gene signatures and magnetic beads assays.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

We initiated validation studies of our novel diagnostics using multiple samples from cancer patients, and explored their translation and potential appeal for industry.